The BLISS study: Beta-Lactam infusion in severe sepsis-randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis in a Malaysian ICU setting

Abdul Aziz, Mohd. Hafiz and Sulaiman, Helmi and Mat Nor, Mohd Basri and Rai, Vineya and Wong, K. and Hasan, Mohd Shahnaz and Wallis, Steven C and Lipman, Jeffrey and Staatz, Christine E. and Roberts, Jason A. (2015) The BLISS study: Beta-Lactam infusion in severe sepsis-randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis in a Malaysian ICU setting. In: Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and 28th International Congress of Chemotherapy (ICC) Meeting (ICAAC/ICC 2015), 17-21 September 2015, San Diego, CA. (Unpublished)

	PDF - Presentation Restricted to Repository staff only Download (1MB) | Request a copy
	PDF - Published Version Restricted to Repository staff only Download (157kB) | Request a copy

Abstract

Background: This study aims to determine if continuous infusion (CI) of beta-lactam antibiotics achieves the pharmacokinetic/pharmacodynamic (PK/PD) targets for time-dependent bacterial killing and/or are associated with improved clinical outcomes compared to intermittent bolus (IB) dosing in critically ill patients with severe sepsis. Methods: This is a report from the BLISS Study which was a prospective, multicentre, open-labelled, randomised, controlled trial of CI vs IB dosing of beta-lactam antibiotics, recruiting critically ill patients with severe sepsis from two Malaysian ICUs. The primary end-point, PK/PD target attainment, was evaluated at the halfway point and end of the dosing interval on days 1 and 3 of treatment, by comparing beta-lactam concentrations against causative pathogens based on EUCAST MIC. Secondary end-points were number of days before patient’s white blood cell (WBC) count normalised and that patient’s required infection-related mechanical ventilation (MV), as well as 14-day mortality. Results: 140 critically ill patients with severe sepsis were enrolled with 70 patients each randomly allocated to the CI and IB treatment arms. APACHE II (CI 22 vs IB 20, p = 0.336) and SOFA (CI 9 vs IB 8, p = 0.217) scores were similar between CI and IB patients. CI patients demonstrated numerically higher PK/PD target attainment rates compared to IB patients at the halfway point (CI 96.6% vs IB 83.9%, p = 0.022) and end (CI 96.6% vs IB 62.5%, p < 0.001) of the dosing interval on Day 1, and at the halfway point (CI 100.0% vs IB 85.7%, p = 0.003) and end (CI 98.2% vs IB 58.9%, p < 0.001) of the dosing interval on Day 3, respectively. WBC count normalisation (CI 4 vs IB 6 days, p = 0.014) and infection-related MV (CI 6 vs IB 9 days, p = 0.038) were shorter for CI patients. Mortality rates (CI 17.7% vs IB 16.0%, p = 0.807) were similar between CI and IB patients. Conclusion: Preliminary results of the BLISS study provide additional PK/PD and clinical outcome data to support the practice of CI administration of beta-lactam antibiotics in critically ill patients with severe sepsis.

Item Type:	Conference or Workshop Item (Slide Presentation)
Additional Information:	6561/44991
Uncontrolled Keywords:	beta-lactams; ICU; pharmacokinetic-pharmacodynamic
Subjects:	R Medicine > RM Therapeutics. Pharmacology > RM300 Drugs and their action R Medicine > RS Pharmacy and materia medica
Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button):	Kulliyyah of Pharmacy > Department of Pharmacy Practice
Depositing User:	Mohd Hafiz Abdul Aziz
Date Deposited:	30 Nov 2015 15:27
Last Modified:	15 Jul 2020 10:57
URI:	http://irep.iium.edu.my/id/eprint/44991

Actions (login required)

View Item